JPH10509421A5 - - Google Patents
Info
- Publication number
- JPH10509421A5 JPH10509421A5 JP1996511844A JP51184496A JPH10509421A5 JP H10509421 A5 JPH10509421 A5 JP H10509421A5 JP 1996511844 A JP1996511844 A JP 1996511844A JP 51184496 A JP51184496 A JP 51184496A JP H10509421 A5 JPH10509421 A5 JP H10509421A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/316,341 US6365787B1 (en) | 1994-09-30 | 1994-09-30 | Compounds for the suppression of HIV TAT transactivation |
| US08/316,341 | 1994-09-30 | ||
| PCT/US1995/011779 WO1996010549A1 (en) | 1994-09-30 | 1995-09-22 | Compounds for the suppression of hiv tat transactivation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006184646A Division JP2006273869A (ja) | 1994-09-30 | 2006-07-04 | Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH10509421A JPH10509421A (ja) | 1998-09-14 |
| JPH10509421A5 true JPH10509421A5 (enExample) | 2005-03-10 |
| JP3966900B2 JP3966900B2 (ja) | 2007-08-29 |
Family
ID=23228649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51184496A Expired - Lifetime JP3966900B2 (ja) | 1994-09-30 | 1995-09-22 | Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 |
| JP2006184646A Withdrawn JP2006273869A (ja) | 1994-09-30 | 2006-07-04 | Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006184646A Withdrawn JP2006273869A (ja) | 1994-09-30 | 2006-07-04 | Ｈｉｖ・ｔａｔトランス活性化を抑制するための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6365787B1 (enExample) |
| EP (1) | EP0783474B1 (enExample) |
| JP (2) | JP3966900B2 (enExample) |
| CN (2) | CN100413835C (enExample) |
| AT (1) | ATE403635T1 (enExample) |
| AU (1) | AU700481B2 (enExample) |
| CA (1) | CA2200991C (enExample) |
| DE (1) | DE69535804D1 (enExample) |
| ES (1) | ES2312168T3 (enExample) |
| WO (1) | WO1996010549A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| WO1999017609A1 (en) * | 1997-10-07 | 1999-04-15 | Larreacorp, Ltd. | Nontoxic extract of larrea tridentata and method of making the same |
| US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| US20030219407A1 (en) * | 2002-05-15 | 2003-11-27 | The Regents Of The University Of California | RNA silencing in animals as an antiviral defense |
| US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| US7728036B2 (en) * | 2003-05-20 | 2010-06-01 | Erimos Pharmaceuticals, Llc | Methods for delivery of catecholic butanes for treatment of tumors |
| AU2004249123A1 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| CN100440843C (zh) * | 2004-05-12 | 2008-12-03 | 华为技术有限公司 | 一种环网及其业务实现方法 |
| US8440648B2 (en) * | 2004-07-20 | 2013-05-14 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
| JP5069130B2 (ja) * | 2005-01-27 | 2012-11-07 | エリモス・ファーマスーティカルズ・エルエルシー | Ｎｄｇａ化合物を包含するカテコールブタンの送達のための経口用製剤 |
| CN101150955B (zh) * | 2005-01-27 | 2013-04-17 | 埃里莫斯医药品有限公司 | 递送包括ndga化合物的儿茶酚丁烷的口服制剂 |
| EP1996174A2 (en) * | 2006-02-23 | 2008-12-03 | Erimos Pharmaceuticals LLC | Methods of treating influenza viral infections |
| ES2476249T3 (es) * | 2006-10-02 | 2014-07-14 | Erimos Pharmaceuticals Llc | Derivados del NDGA tetrasustituidos por medio de enlaces éter y enlaces carbamatos y sus síntesis y usos farmacéuticos |
| US9067875B2 (en) | 2006-10-02 | 2015-06-30 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| ES2588235T3 (es) * | 2007-05-11 | 2016-10-31 | Convatec Technologies Inc. | Dispositivo de ostomía |
| US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| MX2011004824A (es) * | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
| US20130331414A1 (en) * | 2011-01-10 | 2013-12-12 | Susana Valente | Inhibitors of Retroviral Replication |
| WO2013116821A1 (en) * | 2012-02-03 | 2013-08-08 | The Johns Hopkins University | Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer |
| SG11201500397XA (en) * | 2012-07-18 | 2015-03-30 | Univ Johns Hopkins | Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid |
| US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008294A (en) | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
| US5276060A (en) * | 1979-06-19 | 1994-01-04 | Block/Chemex, G.P. | Methods of treating tumors with compositions of catecholic butanes |
| DE3009542A1 (de) | 1980-03-13 | 1981-09-24 | Henkel KGaA, 4000 Düsseldorf | Desodorierende kosmetische zusammensetzungen |
| US4774229A (en) | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
| US4880637A (en) * | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
| FR2632956B2 (fr) * | 1988-05-13 | 1991-07-12 | Pasteur Institut | Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus |
| US5559149A (en) | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
| US5195965A (en) * | 1991-03-07 | 1993-03-23 | Shantha Totada R | Method and apparatus for localized treatment of human viral infections and cancers |
| US5646186A (en) | 1994-05-17 | 1997-07-08 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
| US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
| US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| US6071949A (en) | 1995-03-14 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| US5837252A (en) * | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
| US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| KR100645448B1 (ko) | 1996-11-20 | 2006-11-13 | 예일 유니버시티 | 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법 |
| US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
-
1994
- 1994-09-30 US US08/316,341 patent/US6365787B1/en not_active Expired - Lifetime
-
1995
- 1995-09-22 AT AT95933830T patent/ATE403635T1/de not_active IP Right Cessation
- 1995-09-22 WO PCT/US1995/011779 patent/WO1996010549A1/en not_active Ceased
- 1995-09-22 EP EP95933830A patent/EP0783474B1/en not_active Expired - Lifetime
- 1995-09-22 CN CNB2005100743359A patent/CN100413835C/zh not_active Expired - Fee Related
- 1995-09-22 JP JP51184496A patent/JP3966900B2/ja not_active Expired - Lifetime
- 1995-09-22 CN CNB951960350A patent/CN1211335C/zh not_active Expired - Fee Related
- 1995-09-22 CA CA002200991A patent/CA2200991C/en not_active Expired - Fee Related
- 1995-09-22 AU AU36339/95A patent/AU700481B2/en not_active Ceased
- 1995-09-22 DE DE69535804T patent/DE69535804D1/de not_active Expired - Fee Related
- 1995-09-22 ES ES95933830T patent/ES2312168T3/es not_active Expired - Lifetime
-
1996
- 1996-04-04 US US08/627,588 patent/US5663209A/en not_active Expired - Lifetime
-
1997
- 1997-06-25 US US08/882,499 patent/US6291524B1/en not_active Ceased
-
2003
- 2003-09-17 US US10/664,050 patent/USRE40246E1/en not_active Expired - Lifetime
-
2006
- 2006-07-04 JP JP2006184646A patent/JP2006273869A/ja not_active Withdrawn